Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials. [electronic resource]
Producer: 20200929Description: 157 p. digitalISSN:- 1471-2407
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Australia -- epidemiology
- Azetidines -- administration & dosage
- Clinical Trials as Topic -- statistics & numerical data
- Exanthema -- chemically induced
- Female
- Humans
- Incidence
- Male
- Melanoma -- drug therapy
- Middle Aged
- Neoplasm Staging
- Piperidines -- administration & dosage
- Risk Factors
- Sex Factors
- Skin Neoplasms -- drug therapy
- Vemurafenib -- administration & dosage
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.